Developing an ADC, AOC, RDC, or bispecific? Schedule a meeting with our experts at our stand during CPHI Milan 2026, 6-8 October, to discover how we can streamline and de-risk your drug development journey.  Our scientific and commercial leadership welcome the opportunity to schedule some time to connect on your project-specific needs and to provide you with an update on our newly expanded global discovery, development, and manufacturing capabilities.

From antibodies (mAbs) to recombinant vaccines and bioconjugates – including ADCs, RDCs (radioconjugates), and AOCs (antibody-oligonucleotide conjugates)– our team appreciates the chance to share how Abzena can assist in moving your program forward faster to its next milestone. With over two decades of expertise, 2000+ conjugates developed and 200+ cell lines, we come equipped with the technical know-how and state-of-the-art technologies needed to deliver a simplified and secure supply chain.

We can also provide you with an update on our expanded global capabilities and enhanced platform technology like AbZelectPRO™, our GMP-ready cell line development solution. AbZelectPRO™ means you can achieve stable pools in 3 weeks, accelerate from DNA to RCB in just 10 weeks and GMP in 6 months. If you are ready to achieve more from your cell line and reach IND faster, discover AbZelectPRO™.

We look forward to the discussion!